{"name":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","slug":"cspc-zhongnuo-pharmaceutical-shijiazhuang-co-ltd","ticker":"","exchange":"","domain":"cspczhongnuoshijiazhuang.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Liposomal cytarabine-daunorubicin for injection","genericName":"Liposomal cytarabine-daunorubicin for injection","slug":"liposomal-cytarabine-daunorubicin-for-injection","indication":"Acute myeloid leukemia (AML)","status":"phase_3"},{"name":"SYH2053injection","genericName":"SYH2053injection","slug":"syh2053injection","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"SYH2053","genericName":"SYH2053","slug":"syh2053","indication":"Type 2 diabetes","status":"phase_3"},{"name":"SYH2053/placebo injection","genericName":"SYH2053/placebo injection","slug":"syh2053-placebo-injection","indication":"Hypercholesterolemia","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Amphotericin B liposome for injection","genericName":"Amphotericin B liposome for injection","slug":"amphotericin-b-liposome-for-injection","indication":"Fungal infections","status":"phase_1"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Cleviprex®","genericName":"Cleviprex®","slug":"cleviprex","indication":"Acute hypertension (perioperative and postoperative settings)","status":"marketed"}]}],"pipeline":[{"name":"Amphotericin B liposome for injection","genericName":"Amphotericin B liposome for injection","slug":"amphotericin-b-liposome-for-injection","phase":"phase_1","mechanism":"Interferes with fungal cell membrane function","indications":["Fungal infections"],"catalyst":""},{"name":"Cleviprex®","genericName":"Cleviprex®","slug":"cleviprex","phase":"marketed","mechanism":"Cleviprex is a dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, causing vasodilation and reducing blood pressure.","indications":["Acute hypertension (perioperative and postoperative settings)"],"catalyst":""},{"name":"Liposomal cytarabine-daunorubicin for injection","genericName":"Liposomal cytarabine-daunorubicin for injection","slug":"liposomal-cytarabine-daunorubicin-for-injection","phase":"phase_3","mechanism":"This liposomal formulation delivers cytarabine and daunorubicin directly into leukemic cells, where both drugs inhibit DNA synthesis and induce apoptosis.","indications":["Acute myeloid leukemia (AML)","Acute lymphoblastic leukemia (ALL)","Lymphomatous meningitis"],"catalyst":""},{"name":"SYH2053","genericName":"SYH2053","slug":"syh2053","phase":"phase_3","mechanism":"SYH2053 is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"SYH2053/placebo injection","genericName":"SYH2053/placebo injection","slug":"syh2053-placebo-injection","phase":"phase_3","mechanism":"SYH2053 is a monoclonal antibody targeting PCSK9.","indications":["Hypercholesterolemia"],"catalyst":""},{"name":"SYH2053injection","genericName":"SYH2053injection","slug":"syh2053injection","phase":"phase_3","mechanism":"SYH2053 is a monoclonal antibody targeting PD-1.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE13TFU3VEx6NzVjZERyd1lWMkpYdnhQbUNBTE5hYmxRTFphNmJLX0J4dmRWa3RGTG1GX254VUlXSV9Cand2WEJveXFZamM4VktCMzRaN05UTFl1a20xSEJTT21iYUlMdUF0VGRNbHJLX1I0aXM?oc=5","date":"2021-02-16","type":"pipeline","source":"Fortune Business Insights","summary":"Vitamin B12 Market Size, Share, Growth | Industry Report [2034] - Fortune Business Insights","headline":"Vitamin B12 Market Size, Share, Growth | Industry Report [2034]","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOdmZlN2FoYjk2UlBZNG9JdW9uZENla095VUdGamZtQ0lNelVEOG55UnAtMERuME1GYjVRcFhkQ21Pc0ZobHczUXNVR0p3MldyZjhjSHB4ekJWUEpDX01keUh3N3dKUW9ILWhGTDN0OWhhNGhQZ0xyaHlSc05hbVBndWxFZDhMSktkR1Zla0kzZ3YzRnFtcHpYNXFUX1RoSDdSSmdmX2hJQmR1ckdnb3c?oc=5","date":"2016-02-10","type":"regulatory","source":"RAPS.org","summary":"US FDA Inspections in China: An Analysis of Form 483s from 2015 - RAPS.org","headline":"US FDA Inspections in China: An Analysis of Form 483s from 2015","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_1":1,"marketed":1,"phase_3":4},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}